Biomarkers predict outcome in Charcot-Marie-Tooth disease 1A

Conclusions
In summary, we provide evidence that cutaneous transcripts in patients with CMT1A serve as disease severity and progression biomarkers and, if implemented into clinical trials, they could markedly accelerate the development of a therapy for CMT1A.

Source: Journal of Neurology, Neurosurgery and Psychiatry - October 9, 2017 Category: Neurosurgery Authors: Fledrich, R., Mannil, M., Leha, A., Ehbrecht, C., Solari, A., Pelayo-Negro, A. L., Berciano, J., Schlotter-Weigel, B., Schnizer, T. J., Prukop, T., Garcia-Angarita, N., Czesnik, D., Haberlova, J., Mazanec, R., Paulus, W., Beissbarth, T., Walter, M. C., TR Tags: Neuromuscular Source Type: research